Epidarex sells Enterprise Therapeutics' lead program

Roche is acquiring Enterprise Therapeutics' lead program from Epidarex Capital.

7 October 2020•3 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Healthcare M&A Deals Briefs